Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97

Benzinga Newsdesk www.benzinga.com Positive 91.6%

Neg 0% Neu 0% Pos 91.6%

Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $95 to $97.